Research Use Only
Semaglutide vs Retatrutide
Neutral RUO comparison of Semaglutide and Retatrutide using public protocol-library fields: vial size, research class, mechanism, evidence level and references.
Public fields onlyReferences included
This page compares only public, research-context fields from the AllPeptides protocol library. It is not a ranking, recommendation, safety comparison or human-use guide.
Public research comparison fields
| Field | Semaglutide | Retatrutide |
|---|---|---|
| Name | Semaglutide | Retatrutide |
| Representative vial size | 2.5mg | 5mg |
| Research class | Metabolic research | Metabolic research |
| Mechanism context | Semaglutide mimics GLP-1, enhancing glucose-dependent insulin secretion, reducing glucagon, slowing gastric emptying and reducing appetite through central mechanisms. | Retatrutide is the first triple agonist that simultaneously activates three key metabolic hormone receptors: GLP-1, GIP and glucagon. This triple mechanism produces synergistic effects on appetite suppression, energy expenditure and glucose metabolism. The GLP-1 component reduces appetite and slows gastric emptying; GIP enhances insulin secretion and supports fat metabolism; glucagon receptor activation increases energy expenditure and promotes fat oxidation. In clinical trials, participants receiving 12 mg weekly recorded a mean change of 24% in their body weight over 48 weeks. |
| Evidence level | Not specified in profile | Not specified in profile |
Combined references
- NEJM — STEP 1 — Semaglutide 2.4mg for obesity
View source - NEJM — SELECT — Semaglutide cardiovascular benefits
View source - New England Journal of Medicine (2023) — Triple-Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2, 48 weeks
View source - JAMA Network (2023) — Retatrutide Phase 2: 24% weight change at 12 mg weekly
View source - The Lancet (2023) — Retatrutide in type 2 diabetes: Phase 2 (weight change and glycemic outcomes)
View source - Katsi V et al. Biomolecules 2025 — Retatrutide-A Game Changer in Obesity Pharmacotherapy.
View source - Abdrabou Abouelmagd A et al. Proc (Bayl Univ Med Cent) 2025 — Efficacy and safety of retatrutide in obesity: systematic review and meta-analysis.
View source - Nature Reviews Endocrinology (2024) — Triple agonists for obesity and diabetes: clinical overview
View source